"We'd hope MYX with Nextstellis is different - we are just talking about "cycles". Regardless of which way they are reported - the growth rates are similar and unfortunately the last few months have been flat. Reporting type is semantics as the market is wanting revenue growth for a product that has cost Hundreds and Hundreds and Hundreds of $millions."
The definition of semantics is "meaning the same thing", clearly IQVIA cycles (as presented in May) are 23% lower on average than demand cycles (as presented in Feb), so not the same thing and not semantics. I am sure Mithra would not have been happy to be paid licence fees based on IQVIA cycles which are 23% lower. So cycles ain't cycles.
As far as cycles growth rates, this year's growth average is 4.6%, not great but not flat and I agree that the market wants to see revenue growth but no figures have been made available but I am sure that if demand cycles had been presented instead of IQVIA cycles, the market might be factoring in revenue growth of a different kind.
- Forums
- ASX - By Stock
- MYX
- Nextstellis figures
MYX
mayne pharma group limited
Add to My Watchlist
0.40%
!
$5.02

Nextstellis figures, page-11
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.02 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M |
Open | High | Low | Value | Volume |
$5.05 | $5.09 | $4.96 | $774.1K | 154.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3317 | $4.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.04 | 1291 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1317 | 4.990 |
1 | 1000 | 4.980 |
1 | 870 | 4.940 |
1 | 10000 | 4.930 |
1 | 2050 | 4.870 |
Price($) | Vol. | No. |
---|---|---|
5.060 | 4919 | 3 |
5.090 | 1100 | 2 |
5.100 | 584 | 1 |
5.110 | 3100 | 1 |
5.120 | 2000 | 1 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online